Trust Company’s Teva Pharmaceuticals TEVA Stock Holding History

Trust Company’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-574	Closed	-$12K	–	357
2018 Q3	$12K	Hold	574	–	–	0.01%	260
2018 Q2	$14K	Hold	574	–	–	0.01%	259
2018 Q1	$10K	Hold	574	–	–	﹤0.01%	278
2017 Q4	$11K	Buy	+574	New	+$8.63K	﹤0.01%	279
2017 Q3	–	Sell	-850	Closed	-$28K	–	324
2017 Q2	$28K	Hold	850	–	–	0.01%	195
2017 Q1	$27K	Hold	850	–	–	0.01%	219
2016 Q4	$31K	Hold	850	–	–	0.02%	212
2016 Q3	$39K	Hold	850	–	–	0.02%	199
2016 Q2	$43K	Hold	850	–	–	0.02%	184
2016 Q1	$45K	Sell	850 -150	-15%	-$8.8K	0.02%	176
2015 Q4	$65.6K	Hold	1,000	–	–	0.03%	153
2015 Q3	$56K	Hold	1,000	–	–	0.03%	168
2015 Q2	$59K	Sell	1,000 -155	-13%	-$9.56K	0.04%	175
2015 Q1	$72K	Buy	+1,155	New	+$67.2K	0.05%	143

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Trust Company's TEVA Position: Q4 2018 in Review

Trust Company sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 574 shares — an estimated $12K sold.

Trust Company first reported a position in TEVA in Q1 2015 and held it in 14 quarters. The position peaked at $72K in Q1 2015. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Trust Company reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Trust Company sold 574 Teva Pharmaceuticals shares in Q4 2018, an estimated $12K.
Trust Company first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 14 quarters.
Trust Company's Teva Pharmaceuticals position peaked at $72K in Q1 2015.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Trust Company's 13F filing for Q4 2018, filed 22 Jan 2019.